Dinja Kruger

MSC.

20142019
If you made any changes in Pure these will be visible here soon.

Research Output 2014 2019

2019

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes

Sobral-Leite, M., Salomon, I., Opdam, M., Kruger, D. T., Beelen, K. J., van der Noort, V., van Vlierberghe, R. L. P., Blok, E. J., Giardiello, D., Sanders, J., van de Vijver, K., Horlings, H. M., Kuppen, P. J. K., Linn, S. C., Schmidt, M. K. & Kok, M., 2019, In : Breast Cancer Research. 21, 1, p. 90 90.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer

Kruger, D. T., Alexi, X., Opdam, M., Schuurman, K., Voorwerk, L., Sanders, J., van der Noort, V., Boven, E., Zwart, W. & Linn, S. C., 6 Sep 2019, In : International Journal of Cancer.

Research output: Contribution to journalArticleAcademicpeer-review

2018

Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences

Kruger, D. T., Beelen, K. J., Opdam, M., Sanders, J., van der Noort, V., Boven, E. & Linn, S. C., 2018, In : British Journal of Cancer. 119, 7, p. 832-839 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access
2014

Biomarker Study Everolimus, een studie van de Borstkanker Onderzoek Groep Nederland

Kruger, D. T., Beelen, S., Sleijfer, M. P. H. M., Jansen, C. R., Jimenez, C. R., Linn, S. C. & Boven, E., 2014, In : Kanker Breed. 6, 2

Research output: Contribution to journalArticlePopular